传染病信息

[1] Azuma M, Yssel H, Phillips JH, et al. Functional expression of B7/BB1 on activated T lymphocytes[J]. J Exp Med, 1993,177(3):845-850. DOI:10.1084/jem.177.3.845.

[2] Li L, Yang L, Jiang D. Research progress of CD80 in the development of immunotherapy drugs[J]. Front Immunol, 2024,15:1496992. DOI:10.3389/fimmu.2024.1496992.

[3] Xiao L, Guan X, Xiang M, et al. B7 family protein glycosylation:Promising novel targets in tumor treatment[J]. Front Immunol,2022, 13:1088560. DOI:10.3389/fimmu.2022.1088560.

[4] Yuan L, Tatineni J, Mahoney KM, et al. VISTA:A mediator of quiescence and a promising target in cancer immunotherapy[J]. Trends Immunol, 2021, 42(3):209-227. DOI:10.1016/j.it.2020.12.008.

[5]张煜，严方，肖易倍. VISTA靶点肿瘤免疫治疗的研究进展[J].中国药科大学学报，2022,53(4):400-409. DOI:10.11665/j.issn.1000-5048.20220403.

[6] Janakiram M, Shah UA, Liu W, et al. The third group of the B7-CD28 immune checkpoint family:HHLA2, TMIGD2, B7x, and B7-H3[J]. Immunol Rev, 2017, 276(1):26-39. DOI:10.1111/imr.12521.

[7] Ahmed M, Cheng M, Zhao Q, et al. Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3[J]. J Biol Chem, 2015,290(50):30018-30029. DOI:10.1074/jbc.M115.679852.

[8]王中一，徐彧. B7分子的表达及其在肿瘤治疗中的意义[J].山东医学高等专科学校学报，2019,41(2):125-128. DOI:10.3969/j.issn.1674-0947.2019.02.023.

[9]范梦科，张奇，陈伟，等.共刺激分子B7家族在骨肉瘤中的研究进展[J].中国肿瘤外科杂志，2021,13(1):90-94. DOI:10.3969/j.issn.1674-4136.2021.01.018.

[10] Tchen J, Simon Q, Chapart L, et al. PD-L1-and IL-4-expressing basophils promote pathogenic accumulation of T follicular helper cells in lupus[J]. Nat Commun, 2024, 15(1):3389. DOI:10.1038/s41467-024-47691-w.

[11] Ruoxin Xu, Ju Gong, Wei Chen, et al. Soluble B7-H5 is a novel diagnostic, severity, and prognosis marker in acute pancreatitis[J]. Biomed Research International, 2021, 2021:1223850. DOI:10.1155/2021/1223850.

[12] Nandi D, Pathak S, Verma T, et al. T cell costimulation, checkpoint inhibitors and anti-tumor therapy[J]. J Biosci, 2020, 45:50.DOI:10.1007/s12038-020-0020-2.

[13] Chen R, Ganesan A, Okoye I, et al. Targeting B7-1 in immunotherapy[J]. Med Res Rev, 2020, 40(2):654-682. DOI:10.1002/med.21632.

[14] Wang J, Wu Y, Lin R, et al. TRAM deletion attenuates monocyte exhaustion and alleviates sepsis severity[J]. Front Immunol,2023, 14:1297329. DOI:10.3389/fimmu.2023.1297329.

[15] Shadbad MA, Hajiasgharzadeh K, Derakhshani A, et al. From melanoma development to RNA-modified dendritic cell vaccines:highlighting the lessons from the past[J]. Front Immunol, 2021,12:623639. DOI:10.3389/fimmu.2021.623639.

[16] Sansom DM, Manzotti CN, Zheng Y. What’s the difference between CD80 and CD86?[J]. Trends Immunol, 2003, 24(6):314-319.DOI:10.1016/s1471-4906(03)00111-x.

[17] Vu C, Thammahong A, Yagita H, et al. Blockade of PD-1attenuated postsepsis aspergillosis via the activation of IFN-gamma and the dampening of IL-10[J]. Shock, 2020, 53(4):514-524.DOI:10.1097/SHK.0000000000001392.

[18] Okagawa T, Konnai S, Goto S, et al. Development of a highaffinity anti-bovine PD-1 rabbit-bovine chimeric antibody using an efficient selection and large production system[J]. Vet Res,2023, 54(1):82. DOI:10.1186/s13567-023-01213-6.

[19] Wang S, Lai JC, Li Y, et al. Loss of CDKN2A enhances the efficacy of immunotherapy in EGFR mutant non-small cell lung cancer[J].Cancer Res, 2025, 85(3):585-601. DOI:10.1158/0008-5472.CAN-24-1817.

[20] Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2pathway from discovery to clinical implementation[J]. Front Immunol, 2016, 7:550. DOI:10.3389/fimmu.2016.00550.

[21] Dey D, Biswas S, Pal S, et al. Monocyte-derived Galectin-9 and PD-L1 differentially impair adaptive and innate immune response in chronic HBV infection and their expression remain unaltered after antiviral therapy[J]. Front Immunol, 2024, 15:1474853.DOI:10.3389/fimmu.2024.1474853.

[22] Piao W, Li L, Saxena V, et al. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration[J]. Nat Commun,2022, 13(1):2176. DOI:10.1038/s41467-022-29930-0.

[23] Hondowicz BD, Batheja AO, Metzgar MH, et al. ICOS expression by effector T cells influences the ability of regulatory T cells to inhibit anti-chromatin B cell responses in recipient mice[J]. J Autoimmun, 2010, 34(4):460-468. DOI:10.1016/j.jaut.2009.11.016.

[24] Yao S, Zhu Y, Zhu G, et al. B7-h2 is a costimulatory ligand for CD28 in human[J]. Immunity, 2011, 34(5):729-740. DOI:10.1016/j.immuni.2011.03.014.

[25] Han Y, Dong Y, Yang Q, et al. Acute myeloid leukemia cells express ICOS ligand to promote the expansion of regulatory T cells[J]. Front Immunol, 2018, 9:2227. DOI:10.3389/fimmu.2018.02227.

[26]张扬，马洁，梁静，等.系统性红斑狼疮患者血清B7-H4、ICOSL水平变化及与IKKβ/NF-κB通路的关系[J].医学动物防制，2023,39(7):634-638. DOI:10.7629/yxdwfz202307005.

[27] Tigabu A. Immunoregulatory protein B7-H3 upregulated in bacterial and viral infection and its diagnostic potential in clinical settings[J]. Front Immunol, 2024, 15:1472626. DOI:10.3389/fimmu.2024.1472626.

[28] Zhao S, Wang Y, Yang N, et al. Genome-scale CRISPR-Cas9screen reveals novel regulators of B7-H3 in tumor cells[J]. J Immunother Cancer, 2022, 10(6):e004875. DOI:10.1136/jitc-2022-004875.

[29] Emaldi M, Rey-Iborra E, Marin A, et al. Impact of B7-H3expression on metastasis, immune exhaustion and JAK/STAT and PI3K/AKT pathways in clear cell renal cell carcinoma[J]. Oncoimmunology, 2024, 13(1):2419686. DOI:10.1080/2162402X.2024.2419686.

[30] Zhang D, Huang H, Gao X, et al. High expression of B7-H3 on monocyte/macrophages in tumor microenvironment promotes lung cancer progression by inhibiting apoptosis[J]. Transl Oncol,2024, 41:101874. DOI:10.1016/j.tranon.2023.101874.

[31] Fabrizio FP, Muscarella LA, Rossi A. B7-H3/CD276 and smallcell lung cancer:What’s new?[J]. Transl Oncol, 2024,39:101801. DOI:10.1016/j.tranon.2023.101801.

[32] Wang JY, Wang WP. B7-H4, a promising target for immunotherapy[J]. Cell Immunol, 2020, 347:104008. DOI:10.1016/j.cellimm.2019.104008.

[33] Ni L, Dong C. New checkpoints in cancer immunotherapy[J].Immunol Rev, 2017, 276(1):52-65. DOI:10.1111/imr.12524.

[34] ElTanbouly MA, Zhao Y, Nowak E, et al. VISTA is a checkpoint regulator for naive T cell quiescence and peripheral tolerance[J]. Science, 2020, 367(6475):eaay0524. DOI:10.1126/science.aay0524.

[35] Xu W, Dong J, Zheng Y, et al. Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression[J]. Cancer Immunol Res,2019, 7(9):1497-1510. DOI:10.1158/2326-6066.CIR-18-0489.

[36] Yi KH, Chen L. Fine tuning the immune response through B7-H3 and B7-H4[J]. Immunol Rev, 2009, 229(1):145-151. DOI:10.1111/j.1600-065X.2009.00768.x.

[37] Bjornsen EG, Thiruchelvam-Kyle L, Hoelsbrekken SE, et al. B7H6is a functional ligand for NKp30 in rat and cattle and determines NKp30 reactivity toward human cancer cell lines[J]. Eur J Immunol, 2019, 49(1):54-65. DOI:10.1002/eji.201847746.

[38] Brandt CS, Baratin M, Yi EC, et al. The B7 family member B7-H6is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans[J]. J Exp Med, 2009, 206(7):1495-1503.DOI:10.1084/jem.20090681.

[39]刘学静，徐燕颖. B7-H6在恶性肿瘤中的研究进展[J].实用肿瘤学杂志，2021,35(1):46-49. DOI:10.11904/j.issn.1002-3070.2021.01.009.

[40] Lee S, Kim JH, Jang IH, et al. Harnessing B7-H6 for anticancer immunotherapy:expression, pathways, and therapeutic strategies[J]. Int J Mol Sci, 2024, 25(19):10326. DOI:10.3390/ijms251910326.

[41] Janakiram M, Chinai JM, Zhao A, et al. HHLA2 and TMIGD2:new immunotherapeutic targets of the B7 and CD28 families[J]. Oncoimmunology, 2015, 4(8):e1026534. DOI:10.1080/2162402X.2015.1026534.

[42] Su Q, Du J, Xiong X, et al. B7-H7:A potential target for cancer immunotherapy[J]. Int Immunopharmacol, 2023, 121:110403.DOI:10.1016/j.intimp.2023.110403.

[43]符圆圆，吴昌平，蒋敬庭.协同刺激分子B7-H7在肿瘤中的表达及机制研究进展[J].临床检验杂志，2020,38(5):363-366. DOI:10.13602/j.cnki.jcls.2020.05.11.

[44] Guo H, Zhang C, Tang X, et al. HHLA2 activates the JAK/STAT signaling pathway by binding to TMIGD2 in hepatocellular carcinoma cells[J]. Inflammation, 2022, 45(4):1585-1599. DOI:10.1007/s10753-022-01644-x.

[45] Wang J, Yang K, Yang X, et al. HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway[J]. Mol Carcinog, 2024, 63(7):1275-1287. DOI:10.1002/mc.23723.

[46] Luu K, Schwarz H, Lundqvist A. B7-H7 is inducible on T cells to regulate their immune response and serves as a marker for exhaustion[J]. Front Immunol, 2021, 12:682627. DOI:10.3389/fimmu.2021.682627.

[47] Costa JP, de Carvalho A, Paiva A, et al. Insights into immune exhaustion in chronic hepatitis B:A review of checkpoint receptor expression[J]. Pharmaceuticals(Basel), 2024, 17(7):964. DOI:10.3390/ph17070964.

[48] Yamagiwa S, Ishikawa T, Waguri N, et al. Increase of soluble programmed cell death ligand 1 in patients with chronic hepatitis C[J]. Int J Med Sci, 2017, 14(5):403-411. DOI:10.7150/ijms.18784.

[49] Wang LT, Wang SN, Chiou SS, et al. HCV core protein-ISX axis promotes chronic liver disease progression via metabolic remodeling and immune suppression[J]. Adv Sci(Weinh), 2023,10(23):e2300644. DOI:10.1002/advs.202300644.

[50] Atsukawa M, Nakatsuka K, Kobayashi T, et al. Ribavirin downmodulates inducible costimulator on CD4+T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance[J].J Gastroenterol Hepatol, 2012, 27(4):823-831. DOI:10.1111/j.1440-1746.2011.06882.x.

[51] Naranjo-Gomez JS, Castillo JA, Rojas M, et al. Different phenotypes of non-classical monocytes associated with systemic inflammation, endothelial alteration and hepatic compromise in patients with dengue[J]. Immunology, 2019, 156(2):147-163.DOI:10.1111/imm.13011.

[52] Lertjuthaporn S, Keawvichit R, Polsrila K, et al. Kinetic changes of peripheral blood monocyte subsets and expression of co-stimulatory molecules during acute Dengue virus infection[J]. Pathogens,2021, 10(11):1458. DOI:10.3390/pathogens10111458.

[54] Raftery MJ, Abdelaziz MO, Hofmann J, et al. Hantavirus-driven PD-L1/PD-L2 upregulation:an imperfect viral immune evasion mechanism[J]. Front Immunol, 2018, 9:2560. DOI:10.3389/fimmu.2018.02560.

[55] Noack D, van den Hout M, Embregts C, et al. Species-specific responses during Seoul orthohantavirus infection in human and rat lung microvascular endothelial cells[J]. PLoS Negl Trop Dis,2024, 18(3):e12074. DOI:10.1371/journal.pntd.0012074.

[56] Li YH, Huang WW, He WQ, et al. Longitudinal analysis of immunocyte responses and inflammatory cytokine profiles in SFTSV-infected rhesus macaques[J]. Front Immunol, 2023,14:1143796. DOI:10.3389/fimmu.2023.1143796.

[57] Rogers MC, Lamens KD, Tollefson SJ, et al. Genetic absence of PD-L1 does not restore CD8(+)T cell function during respiratory virus infection and delays virus clearance[J]. J Virol, 2024,98(10):e79724. DOI:10.1128/jvi.00797-24.

[58] Rutkowska E, Kwiecien I, Klos K, et al. Intermediate monocytes with PD-L1 and CD62L expression as a possible player in active SARS-CoV-2 infection[J]. Viruses, 2022, 14(4):819. DOI:10.3390/v14040819.

[59] Duan L, Reisch B, Mach P, et al. The immunological role of B7-H4in pregnant women with Sars-Cov2 infection[J]. Am J Reprod Immunol, 2022, 88(6):e13626. DOI:10.1111/aji.13626.

[60] Ning H, Chiu SH, Xu X, et al. The immunosuppressive roles of PDL1 during influenza a virus infection[J]. Int J Mol Sci, 2023,24(10):8586. DOI:10.3390/ijms24108586.

[61] Naidoo KK, Ndumnego OC, Ismail N, et al. Antigen presenting cells contribute to persistent immune activation despite antiretroviral therapy initiation during hyperacute HIV-1 infection[J]. Front Immunol, 2021, 12:738743. DOI:10.3389/fimmu.2021.738743.

[62] Xu JC, Chen H, Xu P, et al. Clinical significance of B7-H3expression in circulating CD4(+)CD25(high)T cells, CD14(+)monocytes, and plasma for the progression of HIV infection[J].BMC Infect Dis, 2023, 23(1):462. DOI:10.1186/s12879-023-08411-9.

[63] Yang S, Wang Y, Yu F, et al. Structural and functional insights into the modulation of T cell costimulation by monkeypox virus protein M2[J]. Nat Commun, 2023, 14(1):5186. DOI:10.1038/s41467-023-40748-2.

[64] Jones D, Como CN, Jing L, et al. Varicella zoster virus productively infects human peripheral blood mononuclear cells to modulate expression of immunoinhibitory proteins and blocking PD-L1enhances virus-specific CD8+T cell effector function[J].PLoS Pathog, 2019, 15(3):e1007650. DOI:10.1371/journal.ppat.1007650.

[65]刘丹，王莉琳，任姗，等.免疫检查点抑制剂联合抗血管生成药治疗乙型肝炎相关不可切除肝细胞癌的疗效及安全性[J].传染病信息，2024,37(4):323-328. DOI:10.3969/j.issn.1007-8134.2024.04.007.

[66] Wu L, Zheng Z, Xun J, et al. Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a"shock and kill"strategy for ART-free virological control:a phase II single-arm study[J]. Signal Transduct Target Ther, 2024,9(1):231. DOI:10.1038/s41392-024-01943-9.